IAPT Rec'd PCT/PTO 29 MAR 2006

Approved for use through 3/31/2007. OMB 0651-0021
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

## TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US)

ATTTORNEY'S DOCKET NUMBER 3191US0P

CONCERNING A SUBMISSION	U.S. APPLEAT DI NO (If And Im Sec. 17 SR 1.5)								
INTERNATIONAL APPLICATION NO. INTERNATIONAL FILING DATE PCT/JP2004/014685 September 29, 2004		PRIORITY DATE CLAIMED September 30, 2003							
TITLE OF INVENTION	TITLE OF INVENTION								
THIAZOLINE DERIVATIVE AND USE OF THE SAME APPLICANT(S) FOR DO/EO/US									
Keiji KUBO; Takanobu KUROITA; Masaki KAWAMURA; Hiroki SAKAMOTO									
Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:									
1. This is a FIRST submission of items co	This is a FIRST submission of items concerning a submission under 35 U.S.C. 371.								
2. This is a SECOND or SUBSEQUENT s	This is a SECOND or SUBSEQUENT submission of items concerning a submission under 35 U.S.C. 371.								
This is an express request to begin national examination procedures (35 U.S.C. 371(f)). The submission must include items (5), (6), (9) and (21) indicated below.									
4. The US has been elected (Article 31).	The US has been elected (Article 31).								
5. A copy of the International Applicatio	A copy of the International Application as filed (35 U.S.C. 371(c)(2))								
a. is attached hereto (required	a. is attached hereto (required only if not communicated by the International Bureau).								
b. Las been communicated by	b.  has been communicated by the International Bureau.								
	c. is not required, as the application was filed in the United States Receiving Office (RO/US).								
6. An English language translation of th	An English language translation of the International Application as filed (35 U.S.C. 371(c)(2)).								
a. is attached hereto.	a. Li is attached hereto.								
	b. has been previously submitted under 35 U.S.C. 154(d)(4).								
7. Amendments to the claims of the Inte	Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3))								
a. are attached hereto (requ	a. are attached hereto (required only if not communicated by the International Bureau).								
b. have been communicated	b. have been communicated by the International Bureau.								
c. have not been made; how	c. have not been made; however, the time limit for making such amendments has NOT expired.								
d. have not been made and	d. An have not been made and will not be made.								
8. An English language translation of the	An English language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)).								
9. An oath or declaration of the inventor	An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)).								
10. An English language translation of the Article 36 (35 U.S.C. 371(c)(5)).	An English language translation of the annexes of the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)).								
Items 11 to 20 below concern document(s) or information included:									
11. An Information Disclosure Statement	under 37 CFR 1.97 and 1.98. Cited F	References							
12. An assignment document for recording	ng. A separate cover sheet in compliance w	ith 37 CFR 3.28 and 3.31 is included.							
13. A preliminary amendment.									
14. An Application Data Sheet under 37	An Application Data Sheet under 37 CFR 1.76.								
15. A substitute specification.	A substitute specification.								
16. A power of attorney and/or change o	A power of attorney and/or change of address letter.								
17. A computer-readable form of the seq	A computer-readable form of the sequence listing in accordance with PCT Rule 13ter.2 and 37 CFR 1.821- 1.825.								
18. A second copy of the published Inter	A second copy of the published International Application under 35 U.S.C. 154(d)(4).								
•	A second copy of the English language translation of the international application under 35 U.S.C. 154(d)(4).								
20. Other items or information: Return Posts	Return Postcard; Certificate of Express Mailing; Cover Page International Appln.; Forms PCT/IB/301,304,306,308; ISR Other items or information:								

This collection of information is required by 37 CFR 1.414 and 1.491-1.492. The information is required to obtain or retain a benefit by the public, which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 15 minutes to complete, including gathering information, preparing, and submitting the completed form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Mail Stop PCT, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Page 1 of 2

PTO-1390 (Rev. 12-2004)
Approved for use through 3/31/2007. OMB 0651-0021
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

U.S. APPLICAT	APPLICATION NO. (if known, see 37 CFR 1.5) INTERNATIONAL APPLICATION NO.		ATTORNEY'S DOCKET NUMBER			
10	10/574048 PCT/JP2004/014685		3191US0P			
21. The following	ing fees are submitted:					
a) Basic na	ational fee			\$300.00	\$	
<b>☑</b> b) Examination fee				\$200.00	\$	
<b>☑</b> c) Search fee\$500.00			\$			
	TOTAL OF ABOVE CA			\$1000.00	\$ 1,000.00	
listing or co		led in an ele	d in paper over 100 sheets (ex ctronic medium). The fee is \$			
Total Sheets	Extra sheets	Extra sheets Number of each additional 50 or fraction thereof (round up to a whole number)				
288 - 100 =	188 /50 =	4		x \$250.00	\$ 1,000.00	
Surcharge of \$130.00 for furnishing the oath or declaration later than 30 months from the earliest claimed priority date (37 CFR 1.492(e)).					\$	
CLAIMS	NUMBER FI	LED	NUMBER EXTRA	RATE	\$	
Total claims	27	- 20 =	7	x \$50.00	\$ 350.00	
Independent cla	ims 2	- 3 =	0	× \$200.00	\$	
MULTIPLE DEP	ENDENT CLAIM(S) (if a	oplicable)		+ \$360.00	\$ 360.00	
TOTAL OF ABOVE CALCULATIONS =			\$			
Applicant of by 1/2.	claims small entity status	See 37 CFI	R 1.27. The fees indicated abo	ove are reduced	\$	
			,,,,,,,	SUBTOTAL =	\$ 2,710.00	
_	of \$130.00 for furnishing t date (37 CFR 1.492(f)).	he English t	ranslation later than 30 month	s from the earliest +	\$	
TOTAL NATIONAL FEE =				\$ 2,710.00		
	g the enclosed assignme e cover sheet (37 CFR 3		1.21(h)). The assignment mus 40.00 per property	t be accompanied +	\$	
			TOTAL FE	ES ENCLOSED =	\$ 2,710.00	
	-				Amount to be refunded:	\$
					Amount to be charged:	\$ 2,710.00
a. A chec	ck in the amount of \$		to cover the abov	re fees is enclosed.	···	
b. Please	•	ount No. 5	00799 in the amount of \$		over the above fees.	
c. 🗹 The Co	ommissioner is hereby au	thorized to o	charge any additional fees which	ch may be required,	or credit any overpaymen	nt to Deposit t
d. 🔽 Fees a	re to be charged to a cre	dit card. WA	RNING: Information on this fo	orm may become put	olic. Credit card informat	ion should not
NOTE: Where a	n appropriate time limit	t under 37 C	CFR 1.495 has not been met,		(37/CFR 1.137(a) or (b))	must be filed
	restore the International RESPONDENCE TO:	п Аррисацо	on to pending status.			
				1//	(h	9
Mark Chao, Ph.D., JD  Takeda Pharmaceuticals North America, Inc  SIGNATURE					· · · · · · · · · · · · · · · · · · ·	
475 Half Day		, 1111		Mark C	hao, Ph.D., JD	
·				NAME		
Lincolnshire, IL 60069 USA 37 (847)383-3409 37				,293		
(041)003-331	E 10A (047)303*3403			REGISTRATIO		
				For Custom	er No. 23,115	

FORM PTO-1390 (REV. 12-2004)

Page 2 of 2

# IN THE UNITED STATES PATENT AND TRADEMARK OFFICE 10/574048

Application No.:

Based on PCT/JP2004/014685

Filed:

Intl. Filing 29 SEPTEMBER 2004

1<sup>st</sup> Inventor:

Keiji KUBO

For:

Thiazoline Derivative and Use of the Same

Atty. Dkt. No.

3191 US0P

Art Unit: tb

Examiner:

tba

Allowed:

Batch:

Paper No.:

### **CERTIFICATE OF EXPRESS MAILING UNDER 37 CFR 1.10**

#### USPS EXPRESS MAIL LABEL. No. EV 684084525 US

**DATE IN:** 

March 29, 2006

#### **Itemized Papers/Items:**

- 1. This Certificate of Express Mailing and Return Postcard (2 pages)
- 2. Transmittal Letter for Filing under 35 USC 371 (2 pages X 2)
- 3. Specification total pages (288, including Claims 1-25 (pages 282-287), and Abstract (1 page)
- 4. Copies of Forms PCT/IB/301, 304, 306, 308 (7 pages)
- 5. Copy of Cover Page International Application (WO 2005/030740) (1 page)
- 6. Copy of International Search Report (4 pages)
- 7. Preliminary Amendment (10 pages)
- 8. Credit Card Payment Form (1 page)

The undersigned hereby certifies that the above itemized papers are together being deposited with the Express Mail Post Office to Addressee service of the United States Postal Service (USPS) in an envelope with sufficient postage, having the USPS Express Mail Label No. shown above, and addressed to:

MAIL STOP PCT P.O. BOX 1450

Commissioner for Patents Alexandria, VA 22313-1450

on this date, 3/29/06

Dated: 3/29/06

Gail L. Winokur

Takeda Pharmaceuticals North America, Inc. Intellectual Property Department 475 Half Day Road Lincolnshire, IL 60069 USA